COUSTIC neuroma is the most common tumor in the cerebellopontine angle. Results of a recent epidemiological study have demonstrated an annual incidence of 12.4 tumors per million persons.
G 0 phase. 6, 7 In contrast, PCNA functions as a cofactor from DNA polymerase-delta in the S phase as well as in DNA synthesis associated with DNA repair. 5, 14 In an immunohistochemical study of eight specimens, Lesser and coworkers 12 found that acoustic neuromas can be divided into two distinct groups, one with a Ki-67 index fivefold higher than that of the other group. These authors assumed a relation to tumor growth. In a study in which researchers performed PCNA immunohistochemical analysis of 22 acoustic neuromas, a significantly higher proliferative status was observed in tumors larger than 3 cm. 19 In another study, researchers compared cytophotometric characteristics with histological and proliferation markers in 25 acoustic neuromas and noted a tendency for higher PCNA indices in hyperploid tumors, indicating increased proliferative activity. 18 Charabi and coworkers 1,2 found a significant inverse correlation between duration of symptoms and proliferation index in two series of 21 and 124 acoustic neuromas, but no correlation between tumor size and proliferation.
Results of these studies remain controversial, thus calling for a comprehensive analysis of tumor growth-promoting pathways and clinical data. In this report, we analyzed proliferation of and apoptosis in acoustic neuromas. We demonstrated that tumors larger than 18 mm in diameter grow faster and exhibit enhanced proliferative activity compared with smaller lesions. These data strongly suggest surgical intervention for the treatment of tumors once they become larger than 18 mm in diameter.
Clinical Material and Methods

Patient Population
This study included 34 consecutive adult patients (20 men and 14 women, ranging in age at presentation from 19-72 years [mean 49 years]) who had undergone surgery in the otorhinolaryngology department at the University Hospital, Mainz. Twenty-four tumors were located on the right side, nine on the left (data unavailable in one patient; Table 1 ). Duration of symptoms prior to first diagnosis was assessed, and the maximum tumor size (including both intracanalicular and intracerebral components) was measured on magnetic resonance imaging. Depending on the individual topographical characteristics of each tumor, surgical approaches used were translabyrinthine (four patients), transtemporal (15 patients), and retrosigmoid (15 patients Duration of symptoms prior to presentation ranged from 1 to 120 months, with a mean of 28 months (median 12 months). Common presenting symptoms included sensorineural hearing loss (33.3%), tinnitus (28.8%), and vertigo (23.6%). The maximum tumor diameter ranged from 5 to 36 mm, with a mean of 16.5 mm (median 15 mm).
Immunohistochemical Analysis
Heat-induced antigen retrieval was performed using microwave treatment of all slides (three cycles of 5 minutes at 600 W in 10 mM citrate buffer with a pH of 6) after dewaxing and rehydration. Endogenous peroxidase was blocked by immersing the slides in a solution of 3% H 2 O 2 in methanol. After preincubation with 10% normal serum in 2% bovine serum albumin in PBS for 20 minutes to avoid nonspecific binding, primary antibodies (monoclonal mouse anti-human antibody) were overlaid overnight at 4˚C. Slides were consecutively incubated with biotinylated secondary antibody (mouse immunoglobulin, 1:100; Dako, Hamburg, Germany) for 30 minutes, streptavidin peroxidase (1:100; Dianova, Hamburg, Germany) for 30 minutes, and finally 3,3Јdiaminobenzidine in H 2 O 2 (1.85 mM) for 1 minute. All washing procedures were performed in PBS; dilutions of antibodies were completed in 2% bovine serum albumin in PBS at room temperature. To calculate proliferation indices, positive cells were counted in three randomly selected grids (25 ϫ 25 m) at ϫ 400 magnification and expressed as a percentage of all cells within the three grids (~ 300 cells/grid). Cell counting was performed by the same researcher (A.B.) for minimum variability and later confirmed by a second scientist (J.B.) in a blinded fashion. Sections of moderately differentiated squamous cell carcinomas served as positive controls.
Staining of Apoptosis by the TUNEL Method
For determination of apoptotic cells, a TdT DNA fragmentation kit (Oncogene, Darmstadt, Germany) was used. In brief, sections were dewaxed in xylol, rehydrated through graded alcohols, digested with proteinase K (20 g/l in 10 mM Tris, pH 8) for 15 minutes, and then incubated in 3% H 2 O 2 in methanol for 5 minutes to block endogenous peroxidase activity. For positive control, the slide was incubated for 20 minutes in 1 g/l DNase I in Tris-buffered saline/1 mM MgSO 4 before blocking endogenous peroxidase. After washing with Tris-buffered saline, the slides were incubated with TdT equilibration buffer for 30 minutes, TdT labeling reaction mixture for 2 hours, and then terminated with 0.5 M ethylenediamine tetraacetic acid for 5 minutes. Positive cells were detected by the streptavidin peroxidase staining method (30 minutes) and visualized by applying 3,3Јdiaminobenzidine in H 2 O 2 (15 minutes, 1.85 mM). Counterstaining was performed using methyl green. Sections of moderately differentiated squamous cell carcinomas and DNase I-exposed acoustic neuromas were used as positive controls. 
Statistical Analysis
The Spearman rank-order correlation coefficient was used to measure statistically the correlation between the proliferation indices and patient age or duration of symptoms. The Wilcoxon rank-sum test was used to assess whether differences between the two groups were significant. Using the Bonferroni adjustment, we determined that probability values below 0.01 were significant to the global 5% niveau.
Results
Proliferation was analyzed in 34 samples by using by two antibodies. Stainings positive for Ki-67 were demonstrated in 30 samples and those positive for PCNA were demonstrated in 27 samples ( Table 1, Fig. 1 ). The Ki-67 labeling index varied from 0 to 28.5%, with a mean of 2.8% (median 1.7%). The PCNA labeling index varied from 0 to 64.5%, with a mean of 31.9% (median 32.8%). The correlation coefficient was 0.62 comparing Ki-67 and PCNA (p Յ 0.0001), but we found no correlation between proliferation indices and patient age or duration of symptoms. We established 18 mm as the maximal tumor diameter cutoff, dividing the tumors in two groups-those 18 mm or smaller and those larger than 18 mm-with high and low proliferation indices (p Ͻ 0.0001 for Ki-67 and PCNA). We found complete division for PCNA, that is, large tumors have high PCNA indices and small lesions have low indices. Only one sample larger than 18 mm had a low Ki-67 labeling index (Fig. 2) . The tumors with high proliferative activity (Ki-67 labeling index Ն 2.5% and PCNA labeling index Ն 40%) belonged to the group with high growth rates and vice versa (Fig. 3) . This difference was significant (p = 0.0002 for Ki-67 and p Ͻ 0.0001 for PCNA). We compared maximal tumor size and patient age with respect to proliferative activity of the tumor (Fig. 4) . Again, we distinguished two groups of patients: one with smaller, lower-proliferating tumors and a second group with larger, higher-proliferating tumors.
Programmed cell death (apoptosis) was measured using the TUNEL assay. No apoptotic cells were found in any of the studied samples, with positive controls in DNase I- exposed acoustic neuromas, squamous cell carcinoma, and leukemic cells (HL60; data not shown).
Discussion
In this study, we showed that large acoustic neuromas exhibit enhanced proliferative activity and higher growth rates compared with smaller tumors, having defined a highly significant threshold value of 18 mm for tumor size. Furthermore, we demonstrated that acoustic neuromas possess low apoptotic activity.
The mechanisms leading to acoustic neuroma formation have not been fully elucidated. One might assume that impaired common growth-regulating and -limiting mechanisms like proliferation or apoptosis are involved. Therefore, we analyzed 34 tumor samples by using two independent markers of proliferation, that is, Ki-67 and PCNA.
With both markers we found comparable scores and a statistically significant increase in proliferating cells in tumors larger than 18 mm in diameter. In contrast, results of two immunohistochemical analyses in which Ki-67 was applied to 21 and 124 tumors, Charabi and coworkers 1, 2 showed no significant increase in proliferation with regard to tumor size. Because the average tumor size of 13 mm was comparable to that in our study, any differences remain unclear.
To target the issue of whether tumors accelerate their rate of growth while they enlarge or whether acoustic neuromas might be characterized as slow-or fast-growing per se, we estimated the mean growth rates. We assumed that the onset of tumorigenesis varies randomly and theoretically could even be zero. The growth rate was therefore calculated by dividing the maximal tumor diameter by the patient's age. We found that the tumors with high proliferation indices belong to the group with high growth rates and vice versa (Fig. 3) . This suggests that acoustic neuromas might be classified by size determination in a fast-growing and slowgrowing fraction; that is, large tumors seem to grow faster compared with small lesions.
We also observed that smaller, lower-proliferating tumors occur in patients of all ages, with a tendency toward decreasing proliferative activity in older patients. In contrast, larger, faster-growing lesions are observed mostly in patients younger than 50 years (Fig. 4) . This might indicate that the fast-growing, more aggressive tumors are rare in older patients, whereas the slow-growing tumors appear at any age.
Our results are supported by data from previous immunohistochemical studies 12, 18, 19 and imaging studies conducted by Rosenberg and coworkers, 15 in which patients with tumors smaller than 15 mm at initial evaluation demonstrated no rapid tumor growth. Fucci and coworkers 3 reported that acoustic neuromas larger than 20 mm had a tendency to grow at a faster rate.
Although both PCNA and Ki-67 reactivity strongly correlated with each other, the actual values did vary, with FIG. 3 . Box plot demonstrating high compared with low Ki-67 or PCNA with respect to estimated tumor growth rate. Tumors with high proliferative activity (Ki-67 labeling index Ն 2.5%, PCNA labeling index Ն 40%) grow at faster rates (Ki-67 p = 0.002; PCNA p Ͻ 0.0001).
PCNA demonstrating higher overall counts. 11 Whereas immunostaining for Ki-67 showed clear-cut positive or negative stainings, PCNA staining frequently demonstrated a wide spectrum of immunoreactivity, ranging from strongly positive to moderate, weak, questionably positive, or negative. In addition to the high sensitivity of the technique, the long halflife of the PCNA protein and the existence of nonproliferative, related nuclear PCNA populations may explain its higher labeling index compared with Ki-67 with regard to acoustic neuromas.
The TUNEL method was used in the apoptosis studies, but no apoptotic cells were detected. These results confirm those of a previous analysis of apoptosis in acoustic neuromas. 4 These authors studied the differences in surgical specimens obtained from patients with recurrent tumors after radiosurgery and from those without prior treatment. They found some apoptotic cells in tumor sections after radiosurgery, but none in acoustic neuromas that had not been irradiated. The lack of apoptosis in acoustic neuromas might be caused by the longevity of the underlying Schwann cells. Therefore, one might speculate that the growth of acoustic neuromas is not influenced by dysregulated programmed cell death.
We conclude that proliferative activity and patient age should be considered important factors in the growth of acoustic neuromas and the prognosis of patients harboring them. Patients older than 50 years rarely have fast-growing, large tumors and might do well to undergo observation without operation. In younger patients, tumor size could indicate a fast-growing lesion, which should lead to initiation of therapy.
